Reza Boostani

Reza Boostani

Auto-generated profile, based on publicly available information

Reza Boostani

Department of Neurology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
AMAsadollah Mohammadi
Asadollah Mohammadi
Bahare FazeliBahare Fazeli
Bahare Fazeli
MTMarzieh Taheri
Marzieh Taheri
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar
ZPZohreh Poursina
Zohreh Poursina
HRHoushang Rafatpanah
Houshang Rafatpanah

1 September 2021 in Basic and Clinical Neuroscience Journal
Verified
Journal Article
Open access
PDF file
NKNarges Karimi
Narges Karimi
RBReza Boostani
Reza Boostani
FFFarzad Fatehi
Farzad Fatehi
APAkram Panahi
Akram Panahi
AOAli Asghar Okhovat
Ali Asghar Okhovat
SNShahriar Nafissi
Shahriar Nafissi
Introduction: Guillain-Barre Syndrome (GBS) is an autoimmune acute inflammatory demyelinating polyneuropathy usually elicited by an upper respiratory tract infection. Several studies reported GBS associated with Coronavirus Disease 2019 (COVID-19) infection. In this study, we described nine GBS patients following the COVID-19 vaccine. Methods: In this study, nine patients were introduced from six referral centers for neuromuscular disorders in Iran between April 8 and June 20, 2021. Four patients received the Sputnik V, three patients received the Sinopharm, and two cases received the AstraZeneca vaccine. All patients were diagnosed with GBS evidenced by nerve conduction studies and/or cerebrospinal fluid analysis. Results: The median age of the patients was 54.22 years (ranged 26-87 years), and seven patients were male. The patients were treated with Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PLEX). All patients were discharged with some improvements. Conclusion: The link between the COVID-19 vaccine and GBS is not well understood. Given the prevalence of GBS over the population, this association may be coincidental; therefore, more studies are needed to investigate a causal relationship.

12 November 2018 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
BVBarbara Vona
Barbara Vona
RMReza Maroofian
Reza Maroofian
EBEmanuele Bellacchio
Emanuele Bellacchio
MNMaryam Najafi
Maryam Najafi
KTKyle Thompson
Kyle Thompson
EKEhsan Ghayoor Karimiani
Ehsan Ghayoor Karimiani
IARS2 encodes a mitochondrial isoleucyl-tRNA synthetase, a highly conserved nuclear-encoded enzyme required for the charging of tRNAs with their cognate amino acid for translation. Recently, pathogenic IARS2 variants have been identified in a number of patients presenting broad clinical phenotypes with autosomal recessive inheritance. These phenotypes range from Leigh and West syndrome to a new syndrome abbreviated CAGSSS that is characterised by cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia, as well as cataract with no additional anomalies. Genomic DNA from Iranian probands from two families with consanguineous parental background and overlapping CAGSSS features were subjected to exome sequencing and bioinformatics analysis. Exome sequencing and data analysis revealed a novel homozygous missense variant (c.2625C > T, p.Pro909Ser, NM_018060.3) within a 14.3 Mb run of homozygosity in proband 1 and a novel homozygous missense variant (c.2282A > G, p.His761Arg) residing in an ~ 8 Mb region of homozygosity in a proband of the second family. Patient-derived fibroblasts from proband 1 showed normal respiratory chain enzyme activity, as well as unchanged oxidative phosphorylation protein subunits and IARS2 levels. Homology modelling of the known and novel amino acid residue substitutions in IARS2 provided insight into the possible consequence of these variants on function and structure of the protein. This study further expands the phenotypic spectrum of IARS2 pathogenic variants to include two patients (patients 2 and 3) with cataract and skeletal dysplasia and no other features of CAGSSS to the possible presentation of the defects in IARS2. Additionally, this study suggests that adult patients with CAGSSS may manifest central adrenal insufficiency and type II esophageal achalasia and proposes that a variable sensorineural hearing loss onset, proportionate short stature, polyneuropathy, and mild dysmorphic features are possible, as seen in patient 1. Our findings support that even though biallelic IARS2 pathogenic variants can result in a distinctive, clinically recognisable phenotype in humans, it can also show a wide range of clinical presentation from severe pediatric neurological disorders of Leigh and West syndrome to both non-syndromic cataract and cataract accompanied by skeletal dysplasia.

1 January 2012
Verified
Journal Article
Closed access
RBReza Boostani
Reza Boostani
SDSiavash Derakhshan
Siavash Derakhshan

1 March 2013
Verified
Journal Article
Open access
ASAli Shoeibi
Ali Shoeibi
MEMohammdmahdi Etemadi
Mohammdmahdi Etemadi
AAAmir Moghaddam Ahmadi
Amir Moghaddam Ahmadi
MAMona Amini
Mona Amini
RBReza Boostani
Reza Boostani
Human T-cell lymphotropic virus (HTLV) types 1 and 2 belong to the Oncorna group of retroviridae, a large family of viruses, grouped initially by pathogenic features, but later revised on the basis of genome structure and nucleotide sequence. HTLV-I was the first discovered human retrovirus to be associated with a malignancy in 1980. The malignancy, first described by Uchiyama and co-workers in southwestern Japan, was named Adult T-cell Leukemia/Lymphoma (ATL) and characterized with cutaneous and respiratory involvement, hepatosplenomegaly, lymphadenopathy and various metabolic abnormalities such as hypercalcemia. The HTLV-I has been known to be endemic to certain parts of Iran like the province of Khorasan in the northeast since 1990, with a 2.3% prevalence rate of infection. The main manifestations of HTLV-I infection are neurologic and hematologic (such as ATL) disorders, but it has also other manifestations such as uveitis, arthritis, dermatitis, vitiligo and lymphocytic alveolitis. Its main neurologic manifestation is a chronic progressive myelopathy that is referred to HTLV-I Associated Myelopathy (HAM) in Japan and Tropical Spastic Paraparesis (TSP) in Caribbean. But other disorders such as peripheral neuropathy, polyradiculoneuropathy, myopathy, peripheral facial paresis, and so on have been reported too. In this review we wish to give some brief information on the different aspects (including epidemiology, pathogenesis and pathology, clinical findings, and treatment) of HTLV-I infection according to our twenty-year researches. The department of neurology of Mashhad University of Medical Sciences has been a pioneer in researches on HTLV-I in the last twenty years.

23 December 2022 in Microbial Pathogenesis
Verified
Journal Article
Closed access
MSMorteza Saeidi
Morteza Saeidi
ZVZohreh Vahidi
Zohreh Vahidi
MNMohammad Ali Nahayati
Mohammad Ali Nahayati
MRMajid Khadem Rezaiyan
Majid Khadem Rezaiyan
FZFariba Zemorshidi
Fariba Zemorshidi
HRHoushang Rafatpanah
Houshang Rafatpanah